0 CHECKOUT

Acute Spinal Cord Injury - Pipeline Review, H2 2015

  • ID: 3422664
  • August 2015
  • 52 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Kringle Pharma, Inc.
  • Neuralstem, Inc.
  • Neuronax SAS
  • MORE

Acute Spinal Cord Injury - Pipeline Review, H2 2015

Summary

The report ‘Acute Spinal Cord Injury - Pipeline Review, H2 2015’, provides an overview of the Acute Spinal Cord Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Kringle Pharma, Inc.
  • Neuralstem, Inc.
  • Neuronax SAS
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Acute Spinal Cord Injury Overview

Therapeutics Development

Pipeline Products for Acute Spinal Cord Injury - Overview

Pipeline Products for Acute Spinal Cord Injury - Comparative Analysis

Acute Spinal Cord Injury - Therapeutics under Development by Companies

Acute Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes

Acute Spinal Cord Injury - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Acute Spinal Cord Injury - Products under Development by Companies

Acute Spinal Cord Injury - Products under Investigation by Universities/Institutes

Acute Spinal Cord Injury - Companies Involved in Therapeutics Development

Kringle Pharma, Inc.

Neuralstem, Inc.

Neuronax SAS

Vertex Pharmaceuticals Incorporated

Acute Spinal Cord Injury - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Cell Therapy for Spinal Cord Injury - Drug Profile

Product Description

Mechanism of Action

R&D Progress

KP-100IT - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NSI-566 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NX-210 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Peptides for Central Nervous System and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Acute Spinal Cord Injury - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VX-210 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Acute Spinal Cord Injury - Recent Pipeline Updates

Acute Spinal Cord Injury - Dormant Projects

Acute Spinal Cord Injury - Discontinued Products

Acute Spinal Cord Injury - Product Development Milestones

Featured News & Press Releases

Nov 26, 2013: NX210 receives Orphan Drug Designation in Europe for the treatment of spinal cord injuries

Oct 15, 2012: Neuronax receives 600.000 euros from Oseo to support its NX210 Project

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Acute Spinal Cord Injury, H2 2015

Number of Products under Development for Acute Spinal Cord Injury - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Acute Spinal Cord Injury - Pipeline by Kringle Pharma, Inc., H2 2015

Acute Spinal Cord Injury - Pipeline by Neuralstem, Inc., H2 2015

Acute Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2015

Acute Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Acute Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H2 2015

Acute Spinal Cord Injury - Dormant Projects, H2 2015

Acute Spinal Cord Injury - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Acute Spinal Cord Injury, H2 2015

Number of Products under Development for Acute Spinal Cord Injury - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Kringle Pharma, Inc.
Neuralstem, Inc.
Neuronax SAS
Vertex Pharmaceuticals Incorporated

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Shire PLC.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Roche Diagnostics Ltd.
  • H. Lundbeck A/S
  • Electrical Geodesics, Inc.